300015 爱尔眼科
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入16,301,5001.58%20,367,15716,109,94715,000,80911,912,410
减:营业总成本12,268,2174.38%15,113,23312,152,47810,986,8238,610,759
    其中:营业成本7,984,7453.52%10,021,9757,980,3897,211,8875,833,826
               财务费用140,818120.03%73,6286,655106,44490,352
               资产减值损失(560)-19.06%(383,606)(95,464)(217,209)(362,814)
公允价值变动收益214,301-11,789.76%(79,423)(356,890)(448,391)(380,413)
投资收益148,922431.10%46,52343,910141,116159,039
    其中:对联营企业和合营企业的投资收益------(3)(59)(90)
营业利润4,443,8280.03%4,947,9473,534,5003,493,9982,674,177
利润总额4,347,8281.14%4,551,0193,335,0563,147,7552,363,274
减:所得税费用679,621-12.69%895,023646,059677,852486,105
净利润3,668,2074.20%3,655,9962,688,9972,469,9031,877,169
减:非控股权益216,438-36.20%297,124164,766146,559153,363
股东净利润3,451,7698.50%3,358,8722,524,2312,323,3441,723,805

市场价值指针
每股收益 (元) *0.3758.49%0.3640.2790.3340.326
每股派息 (元) *----0.1500.1000.1200.148
每股净资产 (元) *2.1889.10%2.0212.3232.0922.391
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容